Gene therapy for advanced Parkinson's disease
Part of Brain & nervous system clinical trials.
This trial tests a new gene therapy delivered directly into the brain to help control Parkinson's symptoms. It is for people with advanced Parkinson's disease who still have significant movement problems despite their current medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 45 to 75 years
- Diagnosed with Parkinson's disease more than 10 years ago
- Symptoms not fully controlled, with moderate to severe motor symptoms (Hoehn and Yahr stage III-IV)
- Must have a 30% or more improvement in symptoms after a levodopa dose
- No prior brain surgery for Parkinson's, and no history of cell or gene therapy
- Willing to participate in long-term follow-up after the main study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy for Parkinson's disease. The therapy is delivered directly into the brain during a surgical procedure, with the goal of improving motor symptoms and reducing 'off' time.
This study tests an experimental gene therapy delivered to a specific brain area to help control Parkinson's symptoms. It is for people with advanced Parkinson's whose current medications no longer work well enough.
This trial tests a new gene therapy (AB-1005) for Japanese adults with moderate Parkinson's disease. It aims to see if the treatment can help improve motor symptoms, especially for people who experience fluctuations in how well their medication works.
This trial tests a new gene therapy that may improve movement control in people with Parkinson's disease. It involves a one-time surgical injection into the brain and requires you to be off your usual Parkinson's medications during some assessments.
This trial tests an experimental gene therapy injected directly into the brain, designed for people with Parkinson's disease who carry a specific genetic change called GBA1. The goal is to see if the treatment is safe, tolerable, and helps improve motor symptoms.
This trial tests a new type of gene therapy for Parkinson's disease. It aims to make blocking cells more responsive, improving movement control and reducing symptoms.
Hear when a new PARKINSON DISEASE (Disorder) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.